Biogen Idec reports progress on New Framework for Growth

13 January 2011

“Biogen Idec’s business fundamentals are strong – and we are building on those strengths to transform the company in 2011 and beyond,” said George Scangos, the biotech firm’s chief executive, speaking at the 29th annual JP Morgan Healthcare Conference in San Francisco., outlining progress in the company’s New Framework for Growth.

He said a transformation of Biogen Idec (Nasdaq: BIIB) is underway as the company reports progress on its new Framework for Growth, including:

• Securing top talent to lead R&D with the appointment of Douglas Williams, most recently as CEO of Zymogenetics and Steven Holtzman, chair and former CEO of Infinity Pharmaceuticals, to the newly created position of executive vice president of corporate development (The Pharma Letter January 6).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK